TG6002 – Transgene

Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002

20200908 Transgene TG6002 Phase 1 EN

By nh|2020-09-08T16:07:44+02:00September 8th, 2020|Invir.IO, Press release, TG6002, TG6002|Comments Off

20200220 PR FPI 6002.03 EN

By nh|2020-02-20T16:40:21+01:00February 20th, 2020|Press release, TG6002, TG6002|Comments Off

20190718 - TRANSGENE PR MHRA TG6002

By axc|2019-07-18T17:55:40+02:00July 18th, 2019|Press release, TG6002|Comments Off

20190605 Transgene publi TG4001 TG6002 EN

By Lucie Larguier|2019-06-05T17:48:46+02:00June 5th, 2019|Press release, TG4001, TG6002|Comments Off

20181017 PR TG6002 US

By alcyon|2019-06-03T19:46:36+02:00October 17th, 2018|Press release, TG6002|Comments Off

180820 - TG Tasly Closing EN

By alcyon|2019-06-03T19:45:54+02:00August 20th, 2018|Press release, TG1050, TG6002|Comments Off

180710 - TG Tasly agreement PR

By Lucie Larguier|2019-06-03T19:45:46+02:00July 10th, 2018|Press release, TG1050, TG6002|Comments Off

Johann Foloppe, et al. International Oncolytic Virus Conference, April 2018 [...]

By alcyon|2019-07-01T16:47:54+02:00April 17th, 2018|Publication, TG6002|Comments Off

20171026-PR-TG6002

By nh|2019-06-03T22:18:15+02:00October 26th, 2017|Press release, TG6002|Comments Off

Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 [...]

By alcyon|2019-07-02T10:02:37+02:00July 24th, 2017|Publication, TG6002, TG6002|Comments Off